Stemtech Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 13, 2026, reporting continued operating losses and a widening accumulated deficit for the direct-sales nutritional supplement company.

Key Highlights

  • Quarterly net sales fell sharply: Net sales for the three months ended September 30, 2026 were $282,484, compared with $852,300 in the same period of 2025, according to the filing.
  • Nine-month revenue also declined: Net sales for the nine months ended September 30, 2026 totaled $1,374,753, down from $2,418,271 in the nine months ended September 30, 2025.
  • Operating loss reported: The company recorded an operating loss of $371,398 for Q3 2026 and $1,499,394 for the nine-month period ended September 30, 2026.
  • Accumulated deficit grew: The accumulated deficit reached $36,809,750 as of September 30, 2026, up from $34,877,757 as of December 31, 2025.
  • Share count expanded significantly: Common shares issued and outstanding rose to 2,997,032,856 as of November 13, 2026, from 425,980,711 as of December 31, 2025.
  • Total liabilities exceeded total assets: Total liabilities were $11,221,410 against total assets of $3,108,728 as of September 30, 2026, resulting in total stockholders' equity of negative $8,379,682.

Stemtech's Q3 2026 Financial Position and Operating Results

Stemtech Corporation, a Nevada-incorporated company headquartered in Naples, Florida that markets nutritional supplement products through a direct-sales model, reported sharply lower revenue in its third quarter of 2026. According to the filing, net sales of $282,484 for the three months ended September 30, 2026 represented a significant decrease from the $852,300 recorded in the same quarter a year earlier. Gross profit for Q3 2026 was $213,570, against $682,483 in Q3 2025, with total cost of goods sold of $68,914 for the quarter.

The company's operating expenses for Q3 2026 totaled $584,968, driven primarily by general and administrative costs of $539,193. Commissions, which reflect payouts tied to its direct-sales distribution structure, were $41,637 for the quarter. The filing also disclosed interest expense of $109,526 for the three-month period ended September 30, 2026, compared with $508,699 in Q3 2025. On the balance sheet, notes payable stood at $2,711,999 and convertible debentures net of discount at $1,832,414, with accounts payable and accrued expenses of $5,910,763 as of September 30, 2026.

Intangible assets, net, were listed at $2,083,044 and goodwill at $467,409 as of September 30, 2026. Cash on hand was $255,555, up from $238,245 at December 31, 2025. The filing notes that the company is classified as a smaller reporting company and an emerging growth company. The forward-looking statements contained in the filing are the company's own and are subject to its cautionary language, which notes that "there can be no assurance that the forward-looking statements contained herein will in fact occur."

What Was Disclosed

Stemtech Corporation's 10-Q for the quarter ended September 30, 2026 disclosed declining net sales, widening operating losses, a growing accumulated deficit of $36,809,750, and a large increase in shares outstanding to nearly 3 billion, alongside negative total stockholders' equity of $8,379,682.